Myasthenia Gravis Treatment Market To Reach $4.26 Billion By 2030

Myasthenia Gravis Treatment Market Growth & Trends

The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

 Request a free sample copy or view report summary: Myasthenia Gravis Treatment Market Report

Myasthenia Gravis Treatment Market Report Highlights

• Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).

• The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.

• Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.

• In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.

• Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.

Myasthenia Gravis Treatment Market Market Segmentation

Grand View Research has segmented the global myasthenia gravis treatment market based on treatment type, end-use, and region:

Myasthenia Gravis Treatment Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Cholinesterase Inhibitors

• Chronic Immunomodulators

• Monoclonal Antibodies

• Rapid Immunotherapies

• Thymectomy

• Others

Myasthenia Gravis Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Clinics

• Others

Myasthenia Gravis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Myasthenia Gravis Treatment Market

• Alexion Pharmaceutical Inc.

• Grifols SA

• Avadel Pharmaceuticals, Plc.

• Novartis

• Pfizer, Inc.

• AbbVie Inc.

• F.Hoffmann-La Roche AG

• GlaxoSmithKline Plc.

• Bausch Health Companies Inc.

• Shire plc